(Q39269756)

10 September 2017

title

Mechanism of the antitumoral activity of deferasirox, an iron chelation agent, on mantle cell lymphoma (English)

1 reference

10 September 2017

Liat Vazana-Barad

1

1 reference

10 September 2017

Galit Granot

2

1 reference

10 September 2017

Rahav Mor-Tzuntz

3

1 reference

10 September 2017

Itai Levi

4

1 reference

10 September 2017

Martin Dreyling

5

1 reference

10 September 2017

Ilana Nathan

6

1 reference

10 September 2017

Ofer Shpilberg

7

1 reference

10 September 2017

publication date

2 January 2013

1 reference

10 September 2017

1 reference

10 September 2017

volume

54

1 reference

10 September 2017

issue

4

1 reference

10 September 2017

page(s)

851-859

1 reference

Advances in the understanding of mantle cell lymphoma

10 September 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.734614

Current treatment standards and emerging strategies in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.734614

How I treat mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.734614

Dose-intense treatment of mantle cell lymphoma: can durable remission be achieved?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.734614

Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: res

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.734614

Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.734614

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.734614

Temsirolimus: In relapsed and/or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.734614

Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.734614

Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.734614

Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.734614

Soluble and cell-associated transferrin receptor in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.734614

Prevention of mantle lymphoma tumor establishment by routing transferrin receptor toward lysosomal compartments

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.734614

Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.734614

Antiproliferative and apoptotic effects of iron chelators on human cervical carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.734614

Deferoxamine enhances anti-proliferative effect of interferon-gamma against hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.734614

Iron chelators deferoxamine and diethylenetriamine pentaacetic acid induce apoptosis in ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.734614

Tuning cell cycle regulation with an iron key.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.734614

Exjade(R) (deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.734614

Development of tridentate iron chelators: from desferrithiocin to ICL670.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.734614

Diagnosis of cell death by means of infrared spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.734614

The anti-leukaemic activity of novel synthetic naphthoquinones against acute myeloid leukaemia: induction of cell death via the triggering of multiple signalling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.734614

Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.734614

Functions of cyclin D1 as an oncogene and regulation of cyclin D1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.734614

Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.734614

The evolution of iron chelators for the treatment of iron overload disease and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.734614

Long-term efficacy and safety of deferasirox.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.734614

A reversible arrest point in the late G1 phase of the mammalian cell cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.734614

The new orally active iron chelator ICL670A exhibits a higher antiproliferative effect in human hepatocyte cultures than O-trensox

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.734614

A molecular mechanism for mimosine-induced apoptosis involving oxidative stress and mitochondrial activation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.734614

Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.734614

Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.734614

The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.734614

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.734614

Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.734614

10.3109/10428194.2012.734614

21 January 2018

Identifiers

DOI

1 reference

10 September 2017

1 reference